DNTH logo

DNTH
Dianthus Therapeutics Inc

1,251
Mkt Cap
$4.56B
Volume
349,234.00
52W High
$88.49
52W Low
$13.37
PE Ratio
-20.96
DNTH Fundamentals
Price
$86.20
Prev Close
$85.50
Open
$84.85
50D MA
$64.59
Beta
1.07
Avg. Volume
1.58M
EPS (Annual)
-$4.20
P/B
7.55
Rev/Employee
$22,130.44
$1,188.52
Loading...
Loading...
News
all
press releases
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
Key Points114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026...
Nasdaq News: Markets·1d ago
News Placeholder
More News
News Placeholder
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase & Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 626.4% during the third quarter, according to the company in its most recent filing with...
MarketBeat·2d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 114,367 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 114,367 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a legal filing with the...
MarketBeat·5d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,492,461.00 in Stock
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a document filed...
MarketBeat·6d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - What's Next...
MarketBeat·6d ago
News Placeholder
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·7d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.6% - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Trading 5.6% Higher - Should You Buy...
MarketBeat·12d ago
News Placeholder
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned...
MarketBeat·17d ago
News Placeholder
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH)
Wells Fargo & Company initiated coverage on Dianthus Therapeutics in a report on Thursday. They set an "overweight" rating and a $135.00 target price for the company...
MarketBeat·20d ago
News Placeholder
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Key Points5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter...
Nasdaq News: Markets·20d ago
<
1
2
...
>

Latest DNTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.